Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
EGFR+
Tumour stage
Metastatic
Combined Agent(s)
Erlotinib
Control Arm
Placebo + Erlotinib
Treatment Setting
1st line treatment of NSCLC with EGFR mutation
Trial Name
RELAY

Primary Outcome(s)

Primary Outcome(s)
PFS
Form(s)
Form 2b

Outcome Data

PFS Control
12.4 months
PFS Gain
7 months
PFS HR
0.59 (0.46-0.76)

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
22.04.2020
Release date
22.04.2020

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings